Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;56(4):1079-1088.
doi: 10.1002/jmri.28113. Epub 2022 Feb 14.

Evaluation of Monoexponential, Stretched-Exponential and Intravoxel Incoherent Motion MRI Diffusion Models in Early Response Monitoring to Neoadjuvant Chemotherapy in Patients With Breast Cancer-A Preliminary Study

Affiliations

Evaluation of Monoexponential, Stretched-Exponential and Intravoxel Incoherent Motion MRI Diffusion Models in Early Response Monitoring to Neoadjuvant Chemotherapy in Patients With Breast Cancer-A Preliminary Study

Zyad M Almutlaq et al. J Magn Reson Imaging. 2022 Oct.

Abstract

Background: There has been a growing interest in exploring the applications of stretched-exponential (SEM) and intravoxel incoherent motion (IVIM) models of diffusion-weighted imaging (DWI) in breast imaging, with the focus on differentiation of breast lesions. However, the use of SEM and IVIM models to predict early response to neoadjuvant chemotherapy (NACT) has received less attention.

Purpose: To investigate the value of monoexponential, SEM, and IVIM models to predict early response to NACT in patients with primary breast cancer.

Study type: Prospective.

Population: Thirty-seven patients with primary breast cancer (aged 46 ± 11 years) due to undergo NACT.

Field strength/sequences: A 1.5-T MR scanner, T1 -weighted three-dimensional spoiled gradient-echo, two-dimensional single-shot spin-echo echo-planar imaging sequence (DWI) at six b-values (0-800 s mm-2 ).

Assessment: Tumor volume, apparent diffusion coefficient, tissue diffusion (Dt ), pseudo-diffusion coefficient (Dp ), perfusion fraction (f), distributed diffusion coefficient, and alpha (α) were extracted, following volumetric sampling of the tumors, at three time-points: pretreatment, post one and three cycles of NACT.

Statistical tests: Mann-Whitney test, receiver operating characteristic (ROC) curve. Statistical significance level was P < 0.05.

Results: Following NACT, 17 patients were determined to be pathological responders and 20 nonresponders. Tumor volume was significantly larger in nonresponders at each MRI time-point and demonstrated reasonable performance in predicting response (area under the ROC curve [AUC] = 0.83-0.87). No significant differences between groups were found in the diffusion coefficients at each time-point (P = 0.09-1). The parameters α (SEM), f, and f × Dp (IVIM) were able to differentiate between response groups after one cycle of NACT (AUC = 0.73, 0.72, and 0.74, respectively).

Conclusion: Diffusion coefficients derived from the monoexponential, SEM, and IVIM models did not predict pathological response. However, the IVIM-derived parameters f and f × Dp and the SEM-derived parameter α were able to predict response to NACT in breast cancer patients following one cycle of NACT.

Level of evidence: 2 TECHNICAL EFFICACY STAGE: 2.

Keywords: breast cancer; diffusion-weighted MRI; imaging biomarkers; neoadjuvant chemotherapy; quantitative evaluation.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
MRI scans of a 39‐year‐old woman with invasive ductal carcinoma who was a nonresponder (residual cancer burden [RCB]‐II). Each row includes images acquired pretreatment, after one cycle of neoadjuvant chemotherapy (NACT), and at mid‐treatment. The seeded region of interest (ROI) for the given slice is shown in blue. The tables represent the parameter estimates of monoexponential, stretched‐exponential model (SEM) and intravoxel incoherent motion (IVIM) model at each time‐point.
FIGURE 2
FIGURE 2
The measured diffusion‐weighted imaging (DWI) signals and best‐fit curves of the tumor of the nonresponder patient in Fig. 1 at mid‐treatment.
FIGURE 3
FIGURE 3
MRI scans of a 45‐year‐old woman with invasive ductal carcinoma in the left breast who showed a complete pathological response after surgery (residual cancer burden [RCB]‐0). Each row includes images acquired at pretreatment, after one cycle of neoadjuvant chemotherapy (NACT), and at mid‐treatment. The seeded region of interest (ROI) for the given slice is shown in blue. The tables represent the parameter estimates of monoexponential, stretched‐exponential model (SEM) and intravoxel incoherent motion (IVIM) model at each time‐point. At mid‐treatment, no tumor was visible on the dynamic contrast‐enhanced (DCE) and diffusion‐weighted (DW) images obtained.

Comment in

Similar articles

Cited by

References

    1. Early Breast Cancer Trialists' Collaborative Group . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15‐year survival: An overview of the randomised trials. Lancet 2005;365(9472):1687‐1717. - PubMed
    1. Kaufmann M, Von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 2012;19(5):1508‐1516. - PubMed
    1. Shenoy H, Peter M, Masannat Y, Dall B, Dodwell D, Horgan KJSO. Practical advice on clinical decision making during neoadjuvant chemotherapy for primary breast cancer. Surg Oncol 2009;1(18):65‐71. - PubMed
    1. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228‐247. - PubMed
    1. Hylton NM, Gatsonis CA, Rosen MA, et al. Neoadjuvant chemotherapy for breast cancer: Functional tumor volume by MR imaging predicts recurrence‐free survival—Results from the ACRIN 6657/CALGB 150007 I‐SPY 1 TRIAL. Radiology 2016;279(1):44‐55. - PMC - PubMed

Publication types